Wheeler Bio, a U.S.-based contract development and biomanufacturing organization (CDMO), has partnered with Mitsubishi Corporation to expand its commercial reach and business development activities across the Asia-Pacific region.

Under this partnership, in addition to investing in Wheeler’s Series A-1 financing, Mitsubishi Corporation will leverage its regional network, industry relationships, and commercial expertise to identify and engage Asia-Pacific biotech innovators in Japan, South Korea, India, Singapore, Taiwan and China seeking U.S. development and cGMP manufacturing capabilities.

As Wheeler’s exclusive commercialization partner in the region, Mitsubishi Corporation will support the recruitment of new client relationships and help bridge biologics innovators to Wheeler’s AI/ML enabled ModularCMC platform and cGMP biomanufacturing facility in Oklahoma City. As the demand for U.S. based biomanufacturing increases, Wheeler Bio’s ModularCMC platform is positioned to streamline the path from discovery to clinical development for antibody-based therapeutics, with maximum speed, agility and scalability while offering a High-Touch approach based on timely transparency, scientific rigor and a true partnering mindset.

“Wheeler is honored to have Mitsubishi invest in and partner with Wheeler Bio in support of our business development efforts as we scale the organization,” said Patrick Lucy, President and CEO of Wheeler Bio. “Mitsubishi’s long term domain experience in biologics contract manufacturing is invaluable to our growth objectives.”

“We have long been engaged in the pharmaceutical CDMO market, and we are firmly convinced that Wheeler Bio’s service offerings will provide significant value to clients. Through this strategic partnership, we are confident that the development of biopharmaceutical seeds in the APAC region will be accelerated, ultimately contributing to the improvement of people’s lives,” said Takahiro Tokuda, Healthcare Division COO, Mitsubishi Corporation.